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LPS-induced NFκB enhanceosome 
requires TonEBP/NFAT5 without 
DNA binding
Hwan Hee Lee1, Satoru Sanada2, Seung Min An1, Byeong Jin Ye1, Jun Ho Lee1,  
Young-Kyo Seo1, Changwook Lee1, Whaseon Lee-Kwon1, Christoph Küper3, 
Wolfgang Neuhofer4, Soo Youn Choi1 & Hyug Moo Kwon1
NFκB is a central mediator of inflammation. Present inhibitors of NFκB are mostly based on inhibition 
of essential machinery such as proteasome and protein kinases, or activation of nuclear receptors; as 
such, they are of limited therapeutic use due to severe toxicity. Here we report an LPS-induced NFκB 
enhanceosome in which TonEBP is required for the recruitment of p300. Increased expression of TonEBP 
enhances the NFκB activity and reduced TonEBP expression lowers it. Recombinant TonEBP molecules 
incapable of recruiting p300 do not stimulate NFκB. Myeloid-specific deletion of TonEBP results 
in milder inflammation and sepsis. We discover that a natural small molecule cerulenin specifically 
disrupts the enhanceosome without affecting the activation of NFκB itself. Cerulenin suppresses the 
pro-inflammatory activation of macrophages and sepsis without detectable toxicity. Thus, the NFκB 
enhanceosome offers a promising target for useful anti-inflammatory agents.
Nuclear factor κ B (NFκ B) transcription factors regulate the expression of several hundred cellular 
genes involved in a variety of cellular and physiological processes, such as immune and inflammatory 
responses, developmental processes, cellular growth, and apoptosis1,2. In mammals, five genes encode 
proteins for NFκ B: RelA (p65), RelB, c-Rel, NFκ B1 (p105 which is processed into p50), and NFκ B2 
(p100 which is processed into p52). The protein products form a variety of homo- and hetero-dimers 
to bind DNA, of which the p65:p50 heterodimer is most commonly found. The key regulatory event 
in the activation of the p65:p50 heterodimeric NFκ B is the phosphorylation of Iκ B proteins by the 
Iκ B kinase complex, which leads to Iκ B protein ubiquitination and subsequent degradation2,3. Removal of 
Iκ B leads to the release of cytoplasmic p65:p50 heterodimer, which then moves into the nucleus, associates 
with transcriptional cofactors p300 and CREB binding protein (CBP), and drives the expression of target 
genes. Recent studies have shown that DNA bound NFκ B initiates the formation of distinct enhanceosomes 
in a target gene-specific manner4–7. NFκ B is persistently active in a number of human diseases, including 
sepsis, cancer, arthritis, chronic inflammation, asthma, neurodegenerative diseases, metabolic disease, and 
heart disease8–10, and thus, effective and safe inhibitors of NFκ B would have wide-ranging therapeutic use.
Tonicity-responsive enhancer binding protein (TonEBP), also known as nuclear factor of activated T cells 
5 (NFAT5), belongs to the Rel family of transcriptional factors which include NFκ B and NFAT11,12. TonEBP 
was initially identified as the central regulator of cellular response to hypertonic stress11,13–15. Recent studies 
have demonstrated that TonEBP is involved in the M1 activation of macrophages by promoting the expression 
of pro-inflammatory genes in response to Toll-like receptor activation16,17. TonEBP haplo-deficiency is asso-
ciated with dramatically reduced inflammation and pathology in mouse models of rheumatoid arthritis18 and 
atherosclerosis19.
In order to understand molecular basis of the TonEBP function in inflammation, we investigated TonEBP 
action in the induction of pro-inflammatory genes in response to LPS. Surprisingly, we discover that DNA bind-
ing of TonEBP is dispensable. Instead, TonEBP is required for the activation of NFκ B by way of recruiting tran-
scriptional cofactor p300 through protein-protein interactions. Our data demonstrate that TonEBP is an essential 
component of the LPS-induced NFκ B enhanceosome critical for expression of pro-inflammatory genes.
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Results
TonEBP promotes macrophage activation and sepsis. Macrophage activation is a hallmark of inflam-
mation, and NFκ B is a central regulator of pro-inflammatory macrophage activation20. In order to explore the role 
of TonEBP in macrophage activation, we obtained a line of mice with myeloid-specific deletion of the TonEBP 
gene by crossing the line in which the exon 4 of the TonEBP gene was flanked by lox P sequences (TonEBPfl 
allele)21 with the line expressing the cre recombinase in myeloid cells using the promoter of the lysozyme 2 gene 
(LysM-cre)22. Peritoneal macrophages (PECs) prepared from TonEBPflx/flx, LysM-cre mice showed a dramatically 
reduced TonEBP mRNA expression compared to those prepared from their TonEBPflx/flx littermates (Fig. 1a). 
TonEBP mRNA expression in other tissues such as liver and brain was normal consistent with myeloid-specific 
deletion of the TonEBP gene (data not shown). When stimulated with LPS, PECs from the TonEBPflx/flx, LysM-cre 
mice showed significantly reduced expression of NFκ B-dependent pro-inflammatory genes TNFα and iNOS 
(Fig. 1a), and NO production (Fig. 1b) in response to LPS. In response to D-galactosamine and LPS administra-
tion, which was used to produce a mouse model of sepsis23, the rise in serum TNFα levels were reduced by ~40% 
in the TonEBPflx/flx, LysM-cre mice compared to their TonEBPflx/flx littermates (Fig. 1c). Furthermore, severity of 
sepsis measured by ensuing death was reduced in the TonEBPflx/flx, LysM-cre animals (Fig. 1d). These data show 
that myeloid-specific deletion of the TonEBP gene results in blunted macrophage activation and septic shock in 
association with inflammatory responses.
TonEBP binds to the TNFα promoter without direct interaction with DNA. In macrophages 
TonEBP is induced by Toll-like receptor engagement and activates many genes by direct binding to their promot-
ers including that of TNFα16. Figure 2a shows a schematic representation of 1.6 kb upstream of the mouse TNFα 
gene where three putative binding sites for TonEBP (T1, T2, and T3) and a putative NFκ B binding site (N1) 
are located. In order to understand molecular action of TonEBP, we first examined the affinity of TonEBP and 
NFκ B to the sites using electrophoretic mobility shift assay (EMSA) of nuclear extracts prepared from RAW264.7 
macrophage cell line. The N1 probe detected several prominent bands which showed up after LPS stimulation 
(Fig. 2b). All of these bands were competed away by excess cold probe, but only the top two bands were super-
shifted by p65 antibody but not by TonEBP antiserum indicating that they represented p65-containing NFκ B 
molecules. These data demonstrate that N1 is a functional κ B sequence and p65-containing NFκ B molecules 
have specific affinity to N1.
The macrophage nuclear extracts displayed specific binding to a tonicity-responsive enhancer (TonE) 
sequence (T0) which was enhanced by hypertonicity, supershifted by TonEBP antiserum, and competed away 
by excess cold probe demonstrating that the band represented DNA-bound TonEBP molecules (Fig. 2c). On the 
other hand, none of the putative TonEBP binding sequences T1, T2, and T3 displayed binding to the band, and 
Figure 1. Reduced inflammation and septic death in mice with myeloid-specific deletion of the TonEBP 
gene. (a) Peritoneal macrophages (PECs) isolated from TonEBPflx/flx, LysM-cre (solid bars) and their TonEBPflx/flx  
littermates (open bars) were stimulated for 6 h with LPS or vehicle (V). mRNA expression for TonEBP, TNFα 
and iNOS was measured by RT Q-PCR. (b) PECs were treated for 24 h with LPS or vehicle (V). Nitrite was 
measured using Griess reagent from the media. Mean + SD, n = 5. *p < 0.05. (c) TonEBPflx/flx, LysM-cre mice 
(solid bars) and their TonEBPflx/flx littermates (open bars) were intraperitoneally injected with D-galactosamine 
(700 mg/kg) plus LPS (150 μ g/kg) (GalN/LPS) or vehicle (V). After 1 h, TNFα was measured using ELISA 
from serum samples. Mean + SD, n = 4. *p < 0.05. (d) TonEBPflx/flx, LysM-cre (red line) and their TonEBPflx/flx 
littermates (blue line) were intraperitoneally injected with GalN/LPS. The animals were monitored for 16 h for 
survival n = 15.
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were unable to compete with T0 for TonEBP binding. Thus, T1, T2, and T3 are not a functional TonE and TonEBP 
does not have high affinity for the DNA sequence in the promoter region.
We next performed chromatin immunprecipitation (ChIP) to investigate NFκ B and TonEBP interaction to 
the promoter in situ. p65 bound to the N1 region in LPS-dependent manner (Fig. 2d) as expected from the EMSA 
data above. Surprisingly, TonEBP also displayed LPS-dependent binding to the region. Since TonEBP did not have 
affinity to the sequence in the region, we asked whether there was a protein-protein interaction between TonEBP 
and p65. To address this question, we performed DNA affinity purification analysis (DAPA) of the cell lysates 
using a biotin-labeled N1 probe. Both NFκ B and TonEBP displayed LPS-dependent binding to the N1 probe 
(Fig. 2e) suggesting that there is a protein-protein interaction between them.
TonEBP interacts with p65 through Rel-homology domains (RHDs). Molecular basis of the 
TonEBP-p65 interaction was investigated. Co-immunoprecipitation experiments revealed that both endogenous 
proteins (Fig. 3a) and over-expressed proteins (Fig. 3b) could be mutually pulled down by each other. In order to 
map sites of interaction, we produced various recombinant proteins of TonEBP and p65 (Fig. 4). Analyses of the 
recombinant proteins suggest that the RHDs are critical for both. TonEBP constructs without RHD – TonEBP 
Δ RHD and Yc1 Δ RHD – did not show interaction with p65, while those of intact RHD such as Yc1 and partial 
RHD such as TonEBP Δ IPT did (Fig. 4a). In addition, protein product of a mutant TonEBP allele lacking the 
N-terminal half of RHD did not bind p65 (see below). Likewise, p65 constructs with its RHD domain partially 
deleted (p65 Δ IPT and p65 Δ RHD-n) did not interact with TonEBP (Fig. 4b).
TonEBP stimulates NFκB activity independent of DNA binding. In HEK293 cells, over-expression 
of TonEBP resulted in a stimulation of both κ B-driven and TonE-driven luciferase (Fig. 5a), and expression 
of NFκ B- and TonEBP-target genes (Fig. 5b) as expected. On the other hand, TonEBP Δ RHD, which did not 
interact with p65 (Fig. 4a) and could not bind DNA24, did not stimulate neither κ B-driven nor TonE-driven 
Figure 2. TonEBP binds to the κB site of the TNFα promoter without direct interaction with DNA. 
(a) Schematic representation of putative binding sites of TonEBP (T1, T2, T3) and NFκ B (N1) in the TNFα 
promoter region. DNA sequence of the sites is provided in Methods. (b) Nuclear extracts were prepared from 
RAW264.7 cells stimulated for 1 h with LPS (100 ng/ml) or vehicle (V). EMSA was performed using the nuclear 
extracts and biotin-labeled N1 probe. Where indicated, anti-p65 IgG (p65) or normal IgG (IgG) was added to 
supershift p65-DNA complex; and-TonEBP serum (TonEBP) or normal rabbit serum (Serum) to supershift 
TonEBP-DNA complex. In the last lane, 50 times concentration of unlabeled N1 was added for competition.  
(c) Nuclear extracts were prepared from RAW264.7 cells cultured for 24 h in hypertonic medium containing 
extra 75 mM NaCl (NaCl) or control, isotonic medium (− ). EMSA was performed using the nuclear extracts 
and biotin-labeled probes: T0 (positive control for TonEBP binding), T1, T2 and T3. Anti-TonEBP antibody and 
normal rabbit serum were used to supershift TonEBP-DNA complex. In the last 4 lanes, 50 times concentration 
of unlabeled probe was added for competition. (d) RAW264.7 cells were treated for 1 h with LPS or vehicle 
(V). ChIP was performed using normal rabbit serum, anti-TonEBP serum, normal IgG, and anti-p65 IgG. The 
precipitates were quantified for the N1 region using Q-PCR. A representative set of four independent sets of 
experiments is shown. (e) Cell extracts were prepared from RAW264.7 cells treated for 1 h with LPS or vehicle 
(V). Biotin-labeled N1 probe was used to perform DAPA. DAPA samples and cell lysates were immunoblotted 
for TonEBP and p65. Images of immunoblots are shown on the left, and intensity ratios of TonEBP and p65 in 
DAPA/cell lysate are plotted on the right. A representative set of four independent sets of experiments is shown.
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Figure 3. TonEBP interacts with p65. (a) MEF cell lysates were immunoprecipitated (IP) with normal IgG or 
anti-p65 IgG (left), or normal serum or anti-TonEBP serum (right). The immunoprecipitates and cell lysates 
were immunoblotted for TonEBP and p65 as indicated. (b) COS-7 cells were co-transfected with Myc-p65 and 
Flag-TonEBP. Cell lysates were immunoprecipitated with normal IgG or anti-Myc IgG (left), or anti-Flag IgG 
(right). The immunoprecipitates and cell lysates were immunoblotted for TonEBP, Myc, or Flag as indicated.
Figure 4. TonEBP interacts with p65 via respective RHDs. (a) Schematic representation of human TonEBP 
and its recombinant fragments. RHD, Rel-homology domain – amino acids 280–54424; RHD-n, N-terminal 
subdomain of RHD involved in DNA contact – amino acids 280–444; IPT, Ig-like, plexins, transcription factors 
domain with an immunoglobin-like fold involved in dimer formation – amino acids 445–544. COS-7 cells were 
cotransfected for 24 h with Flag-p65 plus Myc-tagged TonEBP or one of the recombinant TonEBP fragments 
shown. Cell lysates were immunoprecipitated (IP) with anti-Myc antibody. (b) Schematic representation of 
p65 and its fragments. COS-7 cells were cotransfected for 24 h with Myc-Yc1 plus Flag-tagged p65 or one of its 
fragments shown. Cell lysates were immunoprecipitated with anti-Flag antibody.
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gene expression (Fig. 5). TonEBP Δ IPT lacks the dimerization domain and does not bind DNA24. Interestingly, 
TonEBP Δ IPT retained its ability to interact with p65 (Fig. 4a) and stimulated κ B-driven gene expression but not 
TonE-driven gene expression (Fig. 5). These observations demonstrate that TonEBP stimulates NFκ B independ-
ent of DNA binding.
The mouse TonEBP Δ allele was created by deletion of exon 6 and 715. The deletion results in an in-frame 
deletion of 128 amino acids in the N-terminal portion of RDH as depicted in Fig. 6a. Interestingly, mouse embry-
onic fibroblast (MEF) cells established from TonEBPΔ/Δ mice showed reduced κ B-driven luciferase expression 
both in basal conditions and after LPS stimulation (Fig. 6b). Expression of NFκ B-target genes TNFα and Iκ Bα in 
response to LPS was also reduced in these cells (Fig. 6c) consistent with reduced NFκ B activity. We investigated 
molecular basis for the reduced NFκ B activity. The TonEBPΔ/Δ MEF cells expressed the TonEBP Δ protein which 
migrated faster than the wild type TonEBP protein (Fig. 6d). In these cells, expression of the NFκ B subunits – p65, 
RelB, c-Rel, p52, and p50 – was normal. Nuclear localization of p65 and TonEBP in response to LPS looked nor-
mal (Fig. 6e). In addition, serine 276 phosphorylation of p65 in response to LPS was normal in the TonEBPΔ/Δ 
MEF cells (Fig. 6f). Finally, we asked whether reduced TonEBP expression affected DNA binding of p65. 
Knock-down of TonEBP did not affect DNA binding of p65 based on EMSA and DAPA (Supplementary Fig. 1). 
Thus, NFκ B activity was reduced in the TonEBPΔ/Δ MEF cells despite normal expression of NFκ B subunits, 
nuclear translocation, phosphorylation, and DNA binding of p65 in response to LPS. The reduced NFκ B activity 
can be explained by the inability of the mutant protein to interact with p65 (Fig. 7a) providing further support 
to the notion that TonEBP stimulates NFκ B independent of DNA binding, i.e, via protein-protein interaction.
TonEBP is required for the recruitment co-activator p300 to NFκB: LPS-induced NFκB enhan-
ceosome. We asked how the TonEBP-p65 interaction led to stimulation of the NFκ B activity. Two possibil-
ities were explored. One was recruitment of the large and powerful transactivation domain (TAD) of TonEBP25. 
To test this, we generated a fusion protein of p65 and the TAD. The fusion protein displayed a markedly ele-
vated transcriptional activity which was gradually reduced as the TAD domain was serially deleted from the 
C-terminus (Supplementary Fig. 2a,b) as reported earlier25. This observation suggests that the TAD of TonEBP 
Figure 5. Stimulation of NFκB by TonEBP requires the TonEBP-p65 interaction. (a) COS-7 cells were 
transfected with increasing amount of Myc-tagged TonEBP, TonEBPΔ IPT (Δ IPT) or TonEBPΔ RHD (Δ RHD) 
along with κ B-luciferase or Ton E-luciferase reporter construct. Cells were stimulated for 6 hours with LPS 
(100 ng/ml) before measuring luciferase activity. The activity of luciferase is shown relative to those cells 
transfected with empty expression vector. Expression of TonEBP, TonEBPΔ IPT and TonEBPΔ RHD protein 
were examined by immunoblotting with anti-Myc antibody. (b) HEK293 cells were transfected with the 
constructs indicated at the top. mRNA expression was examined by RT Q-PCR for NFκ B-target genes TNFα , 
Iκ Bα , and IL8, and TonEBP-target genes BGT-1, SMIT, and AR. Data are normalized to those transfected with 
empty vector. Mean + SD, n = 5 or 6. *p < 0.05.
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Figure 6. Reduced NFκB activity in TonEBPΔ/Δ MEF cells despite normal expression and regulation of 
NFκB. (a) Schematic representations of TonEBP, TonEBP Δ IPT, TonEBP Δ RHD (see Fig. 3), and protein 
product of the TonEBP Δ allele which lacks exon 6 and 7 leading to an in-frame deletion of a portion of RHD-n 
as indicated. (b) TonEBP+/+ or TonEBPΔ/Δ MEF cells were transfected with the κ B-luciferase construct. Cells  
were treated with LPS (100 ng/ml) or vehicle (V) for 6 hours before measuring luciferase activity. (c) Cells were 
treated with LPS for 6 hours. TNFα and Iκ Bα mRNA were quantified by RT Q-PCR. Mean + SD, n = 4. *p < 0.05.  
(d) Cells were immunoblotted for p65, RelB, c-Rel, p52, p50 and TonEBP. (e) Cells grown on coverslips were 
treated with LPS or vehicle (V), and immunostained for p65 (red) and TonEBP (green). Co-localization is 
shown in orange in merged images. (f) Cells were treated with LPS for 0, 5, and 15 min as indicated, and 
immunoblotted for TonEBP, serine 276 phosphorylated p65 (p-p65), p65, and hsc70.
Figure 7. The TonEBP Δ protein is unable to recruit p300 co-activator to p65. (a) TonEBP+/+ or TonEBPΔ/Δ 
MEF cells were treated with LPS or vehicle (V). Lysates of TonEBP+/+ or TonEBPΔ/Δ MEF cells were 
immunoprecipitated (IP) using anti-p65 antibody followed by immunoblotting for p300, TonEBP and p65. 
(b) Cells were transfected with increasing amount of a p300 expression plasmid along with the κ B-luciferase 
reporter. After 6 h treatment with LPS, luciferase was measured. A representative of three independent 
experiments is shown.
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enhance transactivation by p65 bound to DNA. On the other hand, over-expression of Yc1 (see Fig. 4a), which 
was expected to compete away TAD-containing TonEBP and reduce transactivation of NFκ B, did not inhibit 
NFκ B (Supplementary Fig. 2c) suggesting that there should be other pathways of transactivation by TonEBP.
We explored the possibility that TonEBP was involved in the recruitment of transcriptional co-activators such 
as p300. p300 is an acetyltransferase involved in p65 acetylation which is essential in the assembly of NFκ B 
enhanceosome26. When p65 was immunoprecipitated, both TonEBP and p300 were also brought down (Fig. 7a) 
suggesting that the all the three molecules were in a complex. The interaction increased in response to LPS 
(Fig. 7a) in correlation with increased nuclear localization of p65 (Fig. 6e). Of note, the TonEBP Δ protein did 
not interact with p65 and, thereby, the amount of p300 brought down with p65 was dramatically lower in the 
TonEBPΔ/Δ MEF cells (Fig. 6a, 2nd and 4th lane). The inability of the TonEBP Δ protein to interact with p65 and 
recruit p300 explains the reduced NFκ B activity in the TonEBPΔ/Δ MEF cells (Fig. 6). These data indicate that 
the TonEBP-p65 interaction was critical for the recruitment of p300 to p65. This was further supported by the 
observation that increased expression of p300 did not lead to increased κ B-driven luciferase expression in the 
TonEBPΔ/Δ MEF cells (Fig. 7b). Thus, the inability of the TonEBP Δ protein to transactivate NFκ B was due to its 
inability to interact with p65, i.e., inability to form the NFκ B enhanceosome.
The TonEBP containing enhanceosome complex was characterized further. Knockdown of p300 led to 
reduced recruitment of both p300 and TonEBP to p65 (Supplementary Fig. 3a), while knockdown of p65 did 
not affect the association between p300 and TonEBP (Supplementary Fig. 3b). These observations suggest that 
preformed TonEBP-p300 heterodimer is recruited to p65 after its nuclear translocation in response to LPS. 
Knockdown of TonEBP led to reduced p300 recruitment to p65 (Supplementary Fig. 3c), as expected. Of note, 
ChIP experiments revealed that the LPS-dependent assembly of NFκ B enhanceosome on the promoter of the 
TNFα promoter, as measured by recruitment of p65, Sp1 and Pol II to the N1 site27,28, was reduced after TonEBP 
knockdown (Supplementary Fig. 4). Thus, TonEBP deficiency is associated with not only lower recruitment of 
p300 to p65 but also reduced assembly of the NFκ B enhanceosome on the promoter leading to lower NFκ B activ-
ity observed under these conditions.
Cerulenin disrupts the p65-TonEBP-p300 interaction and inhibits NFκB without toxicity. From 
a screening of natural compounds for inhibition of NFκ B, we discovered that cerulenin, an inhibitor of fatty acid 
synthase29, disrupted the p65-TonEBP-p300 interaction. Cerulenin reduced co-precipitation of TonEBP and p300 
in p65 immunoprecipitation assays both under basal conditions and after LPS treatment (Fig. 8a).
We characterized cerulenin action in molecular detail. Cerulenin inhibited NO production in response to 
LPS in a dose-dependent manner without compromising cell viability (Fig. 8b). The lack of cytotoxicity by ceru-
lenin contrasts with the toxicity of BAY11-7082, a protein kinase inhibitor: while both compounds inhibited NO 
production with comparable efficacy, cerulenin displayed no detectible toxicity unlike BAY11-7082 which dis-
played a dose-dependent decrease in viability (Supplementary Fig. 5). The reduced NO production was associated 
with reduced NFκ B activity based on reduced κ B-driven luciferase expression (Fig. 8c) and reduced expression 
of NFκ B-target genes (Fig. 8d) and their proteins (Fig. 8e). As expected, cerulenin potently inhibited systemic 
inflammation and septic death (Fig. 9). Of great interest, the reduced NFκ B activity was not associated with 
changes in the nuclear localization, DNA binding, or phosphorylation of p65 (Supplementary Fig. 6). In addi-
tion, cerulenin did not affect the expression of TonE-driven luciferase and TonEBP target genes in response to 
hypertonicity (data not shown). Taken together, the data provide compelling evidence that cerulenin prevents 
inflammation by inhibiting NFκ B as it specifically disrupts the p65-TonEBP-p300 interaction. As such, cerulenin 
displayed lower, if any, toxicity.
Discussion
Although the molecular interaction between p300 and p65 subunit of NFκ B was recognized early on30,31, coor-
dinated recruitment of p300 and p65 to the promoters of TNFα and IL-12 genes of macrophages in response to 
LPS was demonstrated fairly recently32. Our date presented here reveal that TonEBP is required for the molecular 
interaction between p300 and p65. Preformed nuclear TonEBP-p300 complex unites with p65 after it enters the 
nucleus in response to LPS (Fig. 10). This p65-TonEBP-p300 complex is unique in that increased TonEBP expres-
sion leads to higher NFκ B activity in correlation with more recruitment of p300; reversely, decreased TonEBP 
expression leads to lower NFκ B activity. This property provides an explanation for the milder inflammation in 
TonEBP haplo-deficient mice: the spike in serum TNFα in response to LPS is reduced (Supplementary Fig. 7) as in 
the mice with myeloid TonEBP deficiency (Fig. 1c). The milder inflammation in TonEBP haplo-deficiency is con-
sistent with reduced inflammatory damages observed in this model: dramatically reduced rheumatoid arthritis18  
and the size of atherosclerotic lesions reduced to one fifth19.
TonEBP was originally identified based on its specific DNA binding to the TonE sequence11. In vivo footprint-
ing analyses revealed that DNA binding of TonEBP to the TonE sites in the promoter regions of its target genes 
temporally correlated with transcriptional stimulation in response to hypertonicity33,34. ChIP experiments have 
shown that the induction of TNFα in response to LPS is associated with TonEBP recruitment to its promoter 
(Fig. 2)16. The data presented here demonstrate that the recruitment is independent of DNA binding. Rather, 
TonEBP is recruited through a protein-protein interaction with NFκ B. We recently reported analogous DNA 
binding-independent recruitment of TonEBP to the promoter of the peroxisome proliferator-activated receptor 
γ gene in association with the suppression of the promoter35.
The histone acetyl transferase activity of p300 is critical for the formation of NFκ B enhanceosome36: After 
recruitment to p65 bound to DNA, p300 acetylates histones leading to opening/remodeling of chromatin and 
binding of proximal factors such as Sp1 and RNA polymerase II. The data presented here are consistent with this 
model in that TonEBP deficiency results in not only reduced recruitment of p300 to the TNFα promoter but also 
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other components of the NFκ B enhanceosome such as Sp1 and RNA polymerase II. Thus, TonEBP-dependent 
recruitment of p300 is a key early step in the formation of NFκ B enhanceosome.
Figure 8. Cerulenin breaks up the TonEBP-p300-p65 interaction and reduces inflammation. (a) MEF 
cells were treated without or with cerulenin (10 μ M) for 1 h followed by vehicle (V) or LPS (100 ng/ml) for an 
additional 1 h. Cell lysates were immunoprecipitated (IP) using anti-p65 antibody. The immunoprecipitates and 
cell lysates were immunoblotted for p300, TonEBP and p65. (b) PECs were treated with 0 to 10 μ M cerulenin 
as indicated for 1 h, followed by LPS for 24 h. Nitrite in the medium (open bars) and cell viability based on 
reduction of MTT (solid bars) were measured. (c) PECs transfected with the κ B-luciferase construct were 
treated with vehicle or cerulenin (10 μ M) for 1 h, followed by vehicle (V) or LPS for an additional 6 h. Luciferase 
activity was measured from cell lysates. Mean + SD, n = 4. *p < 0.05. (d) PECs were treated as in (c) and mRNA 
expression for iNOS, COX-2, TNFα , IL-1β , IL-6 and MCP-1 was measured by RT Q-PCR. Mean + SD, n = 5. 
*p < 0.05. (e) PECs pre-treated for 1 h with vehicle or cerulenin (10 μ M) were stimulated for 24 h with 0, 100, 
and 1,000 ng/ml of LPS. Expression of iNOS and COX-2 was visualized by immunoblotting.
Figure 9. Cerulenin reduces inflammation and septic death in mice. (a) Mice were intraperitoneally injected 
with vehicle or cerlenin (60 mg/kg body weight). After 1 h, vehicle or GalN/LPS was administered as in Fig. 1. 
After another hour, TNFα was measured from serum samples. Mean + SD, n = 5. *p < 0.05. (b) Animals pre-
treated with vehicle (blue line) or cerulenin (red line) were administered with GalN/LPS as in (a). The animals 
were monitored for survival n = 8.
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NFκ B-mediated inflammation is involved in the pathogenesis of a wide range of diseases including cancer3, met-
abolic and vascular disease9, and even viral infection37. Much of the anti-inflammatory activity of the widely used 
glucocorticoids is due to blockage of NFκ B activity38. Genetic and pharmacological inhibition of NFκ B reverses 
insulin resistance in animal models39. A recent clinical trial showed that salicylate, which inhibits NFκ B, improved 
glycemia in patients with type 2 diabetes and decreased inflammatory mediators40. Effective inhibitors of NFκ B with 
minimal side effects would be quite useful for therapeutic use against the diverse inflammatory diseases.
A natural lipid analog cerulenin, (2R)(3S)-2,3-epoxy-4-oxo-7,10-dodecaldienoylamide, is an irreversible 
inhibitor of fatty acid synthase. Here we discover that cerulenin is a powerful inhibitor of NFκ B-mediated inflam-
mation and sepsis. Cerulenin acts by way of disrupting the p65-TonEBP-p300 complex without affecting the 
expression, DNA binding, and regulation of p65 itself (Fig. 10). In this regard it is distinct from most of the known 
NFκ B inhibitors which target broad cellular processes such as protein phosphorylation, proteasome, nuclear 
import machinery, or activation of nuclear receptors. Animals tolerate high doses of cerulenin for many weeks41 
consistent with little cellular toxicity observed in this study. Cerulenin offers an attractive opportunity to develop 
new class of effective and safe anti-inflammatory agents.
Methods
Animals. All the methods involving live mice were carried out in accordance with the approved guidelines. 
All experimental protocols were approved by Institutional Animal Care and Use Committee of the Ulsan National 
Institute of Science and Technology (UNISTACUC-12-15-A).
Mice carrying the loxP-targeted TonEBP gene (TonEBPflx/flx) were reported previously21. Transgenic mice 
expressing Cre recombinase under the control of either the myeloid-specific lysozyme M (LysM) promoter 
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). TonEBPflx/flx and LysM-cre mice crossed 
to yield mice with specific targeted deletion of TonEBP in macrophages (TonEBPflx/flx, LysM-cre). For sep-
tic shock, TonEBPflx/flx, LysM-cre mice and their TonEBPflx/flx littermates were intraperitoneally injected with 
D-galactosamine (700 mg/kg; Sigma Aldrich) plus LPS (150 μ g/kg; Sigma Aldrich). After injection, animals were 
monitored for 16 h for survival.
Cells and Reagents. Macrophage cell line RAW264.7 cells, mouse embryo fibroblasts (MEFs), COS-7 
cells and HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal 
bovine serum (FBS; Thermo fisher scientific Inc, Waltham, MA, USA) and penicillin/streptomycin (100 U/ml 
and 100 μ g/ml; GE healthcare life sciences, Logan, UT, USA). RAW264.7 cells were collected by scraping with a 
rubber policeman, while MEFs, COS-7 cells and HEK293 cells were collected using trypsin/EDTA (Invitrogen, 
Carlsbad, CA, USA). Peritoneal macrophages derived from TonEBPflx/flx and TonEBPflx/flx, LysM-cre mice were 
cultured in RPMI containing 10% fetal bovine serum, penicillin/streptomycin (100 U/ml and 100 μ g/ml). Cells 
were maintained at 37 °C in incubator with 5% CO2. Cells were pretreated with cerulenin and BAY 11-7082 
(Sigma Aldrich, USA) for 1 h and exposed to lipopolysacharide (LPS; Sigma Aldrich). Anti-p65, RelB, c-Rel and 
p52 antibodies from NFκ B family sample kit (4776, Cell Signalling Technologies, Berkeley, CA, USA), anti-p50 
(sc8414, SantaCruz Biotechnology, Santa Cruz, CA, USA City), ser 276 phosphorylated p65 (sc101749, SantaCruz 
Biotechnology), p300 (sc584, SantaCruz Biotechnology) and LaminB (sc6217, SantaCruz Biotechnology) anti-
bodies, anti-Hsc70 (200-301-A28, Rockland, Gilbertsville, PA, USA) and anti-TonEBP antibody10 were used 
for immunoblotting. Cells were transfected with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). siRNA 
duplexes were purchased from Integrated DNA Technologies (Coralville, IA, USA).
Immunoblot assay. Cell lysis for protein extraction was performed as previously described42. Protein con-
centration was measured by BCA protein assay system (Pierce, Rockford, IL, USA). Equal amounts of protein from 
each sample were separated by SDS-PAGE and immunoblotted using specific primary antibodies. HRP-conjugated 
mouse, rabbit and goat secondary antibodies were used for detection. The antigen-antibody binding was detected 
by enhanced chemiluminescence Western blotting detection reagents (GE healthcare life sciences).
RNA isolation and reverse transcription quantitative PCR (RT Q-PCR). Total RNA was isolated 
using the TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. cDNA was synthesized by 
M-MLV reverse transcriptase (Promega, Madison, WI, USA). After reverse transcription, Q-PCR was performed 
Figure 10. Schematic model of NFκB enhanceosome assembly in response to inflammatory stimulation 
and its disruption by cerulenin. See text for details.
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using SYBR Green I Master and LightCycler 480 II (Roche, Rotkreuz, Switzerland). Measured cycle threshold (Ct) 
values were normalized with cyclophilin A and they were expressed as fold-over control samples.
Immunohistocytochemistry. The cells were grown on glass coverslips and fixed with 4% paraformalde-
hyde in PBS (pH 7.4) for 20 min at 4 °C. Cells were permeabilized with 0.3% Triton-X 100 in PBS for 30 min and 
blocked with PBS containing 3% goat serum and 1% bovine serum albumin for 1 h at room temperature. After 
incubation with rabbit anti-TonEBP and rabbit anti-p65 overnight at 4 °C, the cells were washed with PBS and 
treated with goat anti-mouse or anti-rabbit Alexa Fluor 488-conjugated and Alexa Fluor 594-conjugated sec-
ondary antibodies for 1 h. Cells were washed with PBS and incubated in 0.1 μ g/ml Hochest (DAPI) for 30 min. 
After wash with PBS, coverslips were mounted onto microscope slides. Images were recorded using an Olympus 
FV1000 confocal fluorescence microscope.
Nuclear and Cytoplasmic fractionation. Cells were harvested by using scrapper and centrifugation at 
500 g. The cell pellet was washed by suspension with PBS. The cell nucleus and cytoplasm were separated by using 
Nuclear and Cytoplasmic extraction kit (Pierce) according to manufacturer’s instruction. Nuclear fraction was 
confirmed by Lamin B.
Electrophoretic mobility shift assay (EMSA). A commercial kit was used: Lightshift Chemiluminescent 
EMSA kit (Pierce). 5 μ g of nuclear extracts were incubated with poly(dI:dC), binding buffer and 5′ biotinylated DNA 
(N1 – AAACAGGGGGCTTTCCCTCCTC, T1 – GCTCCGTGGAAAACTCACTTGG, T2 – TGTCCCCAACTTT 
CCAAACCCT, T3 – ACCAAGGAAGTTTTCCGAGGGTT, T0-TCATAATGGAAAATTCCATGCCA) at room 
temperature for 20 min. Samples were separated by electrophoresis for 4 h in 4% (40% 29:1 acrylamide/bis solu-
tion) gel for TonEBP and 8% gel for p65. The detection was performed according to manufacturer’s instructions.
Chromatin immunoprecipitation assay. Cells were grown in 10 cm diameter culture dishes and with 
LPS when indicated. Fixation was performed with 1% formaldehyde at room temperature for 10 min. The fixation 
was stopped with 0.125 M glycine for 5 min at room temperature. After three washes with cold PBS, cells were 
collected and lysed in 1 ml of SDS lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl pH 8.1) for 10 min on 
ice. Cell lysates were sonicated (Bioruptor KRB-01, BMS, Tokyo, Japan) for six cycles of 20 s on plus 30 s off with 
constant frequency and maximum intensity to obtain DNA fragments between 400 and 1,000 bp. Each sample 
was diluted 10× in dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 
167 mM NaCl) for immunoprecipitation. Samples were pre-cleared with protein A Sepharose beads (Millipore, 
Bedford, MA, USA) that were previously pre-adsorbed with salmon sperm DNA for 1 h at 4 °C. Specific antibod-
ies were added after removing the pre-clearing beads: anti-p65 IgG, and normal rabbit IgG (Abcam, Cambridge, 
UK), anit-TonEBP serum, and normal rabbit serum (Merck millipore, Darmstadt, Germany). After adding anti-
bodies, the lysates were incubated overnight at 4 °C. Protein A Sepharose beads were then added, incubated for 
2 h at 4 °C, and then washed with low salt washing buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.1, 
2 mM EDTA, and 10 mM NaCl), high salt washing buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.1, 
2 mM EDTA and 500 mM NaCl), LiCl washing buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholic acid, 1 mM EDTA 
and 10 mM Tris-HCl pH 8.1) and twice with final washing buffer (10 mM Tris-HCl pH 8.0 and 1 mM EDTA). To 
elute the DNA, beads were incubated with elution buffer (1% SDS and 100 mM NaHCO3) for 20 min at 65 °C. To 
reverse the cross-linking, samples were incubated overnight at 65 °C 200 mM NaCl, 30 min at 37 °C with 50 μ g/ml 
RNase (Pierce) and 2 hr at 45 °C with 100 μ g/ml proteinase K. DNA was purified using the QIAGEN PCR purifi-
cation system. DNA was then subjected to RT-qPCR using primers; 5′ -CCCAACTCTCAAGCTGCTCT-3′ and 
5′ -CTTCTGAAAGCTGGGTGCAT-3′ for TNFα promoter. Immunoprecipitated DNA from each sample was 
normalized to its respective chromatin input.
DNA affinity purification assay (DAPA). Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 
150 mM NaCl and 0.5% Triton-100). 1 mg of extracts were diluted with binding buffer (4 mM Tris-HCl pH 7.5, 
20 mM HEPES pH 7.5, 5% glycerol, 170 mM NaCl, 0.5 mM EDTA, 1 mM MgCl2 and 0.1% Triton X-100) and 
incubated overnight with 5’ end biotinylated DNA probe (30 nM) containing a κ B site or putative TonE site of 
mouse TNF-α promoter. They were mixed for 2 hr with 50 μ l of streptavidin-coated agarose beads, and protease 
inhibitors (Roche). Beads were pelleted, washed two times with TE buffer with 100 mM NaCl, two times with 
binding buffer, once with PBS and then resuspended in 50 μ l of Laemmli sample buffer. Precipitated proteins were 
separated by 7% SDS-PAGE and immunoblotted for TonEBP and p65.
Luciferase assay. Cells were transfected with either a TonE-driven Photinus luciferase plasmid or a 
κ B-driven luciferase plasmid in pGL4.74 (hRluc/TK, Promega). The Renilla luciferase reporter plasmid (pRL-TK, 
Promega) was used as a control for transfection efficiency. Luciferase activity after 8 h of stimulation was meas-
ured using the Dual-Luciferase Assay System (Promega) according to the manufacturer’s instructions. Luciferase 
activity was normalized by activity of renilla luciferase.
Cytokine production. TNFα  in supernatants from LPS-stimulated cells or serum samples from 
D-Galactosamine (GalN)/LPS-injected mice were analyzed by ELISA using a commercial kit (R&D Systems, 
Minneapolis, MN, USA).
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